Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 9, 2019 and accepted by EDGAR at Aug 8, 2019, 19:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $79.0m | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $158.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $46.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $95.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $32.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $63.3m | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $16.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $30.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $973.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $24.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $54.0k | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $14.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $12.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $47.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | $48.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $0.96 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | $0.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $1.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | $1.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 49,894,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 50,155,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $48.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $24.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2019-01-01 to 2019-06-30 | $4.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-06-30 | $120.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $284.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $601.3m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $101.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $169.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $387.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001297184-19-000038. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.